Daniel Reyes
I've read the Q3 review. 8.2% growth is fine, but what worries me is launch readiness. What exactly is undecided?
Q3 Innovative Medicine Leadership Review · Slide 11
You
There are three open decisions: launch sequencing across priority markets, evidence generation timing, and field force allocation.
Daniel Reyes
And the supply risk? Your deck rates it high impact.
Q3 Innovative Medicine Leadership Review · Slide 18
You
Supply continuity is a risk in two markets, and we're tracking it.